Your browser doesn't support javascript.
loading
Continues administration of Nano-PSO significantly increased survival of genetic CJD mice.
Binyamin, Orli; Keller, Guy; Frid, Kati; Larush, Liraz; Magdassi, Shlomo; Gabizon, Ruth.
Afiliação
  • Binyamin O; Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah University Hospital, 91120 Jerusalem, Israel; Medical School, The Hebrew University, Jerusalem, Israel.
  • Keller G; Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah University Hospital, 91120 Jerusalem, Israel; Medical School, The Hebrew University, Jerusalem, Israel.
  • Frid K; Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah University Hospital, 91120 Jerusalem, Israel; Medical School, The Hebrew University, Jerusalem, Israel.
  • Larush L; Casali Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
  • Magdassi S; Casali Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
  • Gabizon R; Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah University Hospital, 91120 Jerusalem, Israel. Electronic address: gabizonr@hadassah.org.il.
Neurobiol Dis ; 108: 140-147, 2017 Dec.
Article em En | MEDLINE | ID: mdl-28847567
We have shown previously that Nano-PSO, a nanodroplet formulation of pomegranate seed oil, delayed progression of neurodegeneration signs when administered for a designated period of time to TgMHu2ME199K mice, modeling for genetic prion disease. In the present work, we treated these mice with a self-emulsion formulation of Nano-PSO or a parallel Soybean oil formulation from their day of birth until a terminal disease stage. We found that long term Nano-PSO administration resulted in increased survival of TgMHu2ME199K lines by several months. Interestingly, initiation of treatment at day 1 had no clinical advantage over initiation at day 70, however cessation of treatment at 9months of age resulted in the rapid loss of the beneficial clinical effect. Pathological studies revealed that treatment with Nano-PSO resulted in the reduction of GAG accumulation and lipid oxidation, indicating a strong neuroprotective effect. Contrarily, the clinical effect of Nano-PSO did not correlate with reduction in the levels of disease related PrP, the main prion marker. We conclude that long term administration of Nano-PSO is safe and may be effective in the prevention/delay of onset of neurodegenerative conditions such as genetic CJD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Óleos de Plantas / Síndrome de Creutzfeldt-Jakob / Substâncias Protetoras Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Óleos de Plantas / Síndrome de Creutzfeldt-Jakob / Substâncias Protetoras Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article